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1INTRODUCTION
Hypertensive disorders are among the commonest medical
disorders during pregnancy and continue to be a major cause of
maternal and prenatal morbidity and mortality worldwide.  In the
developing countries, they rank second only to anemia, with
approximately 5 to 10 per cent of all pregnancies being
complicated from some form of hypertensive disease.
Hypertensive disorders of pregnancy cover a spectrum of
conditions, of which preeclampsia poses a great risk, complicating
approximately 5 – 8 % of all pregnancies.
Preeclampsia is best described as a pregnancy-specific
syndrome that can affect virtually every organ system.
Preeclampsia is defined as the development of hypertension and
proteinuria for the first time after mid pregnancy.  Although
preeclampsia is much more than simply gestational hypertension
with proteinuria, appearance of proteinuria remains an important
diagnostic criterion.  Proteinuria is the surrogate objective marker
that defines the systemwide endothelial leak, which characterizes
the preeclampsia syndrome.
2Obstetricians currently rely on the 24 hour urine collection for
determination of proteinuria.  However, 24 hour urine collection is
cumbersome, both for the patient and the staff handling the urine
collection and is subject to error due to inaccurate timing and / or
incompleteness.  Further, there is a delay of 24 hours from the time
of collection till the diagnosis is made.
A more rapid test capable of accurately predicting the results
of a 24 hour urine collection would be valuable.  An alternative
method for the quantitative evaluation of proteinuria is the
measurement of protein to creatinine ratio in a spot urine sample.
Clinical utility of urine protein to creatinine ratio as a substitute of
24 hour urine protein excretion for significant proteinuria in patients
with preeclampsia still remains unclear.  Some investigators have
proposed the use of spot urine protein to creatinine ratio.  However,
there are some reports with conflicting results, and the variability in
cut off values between studies does not allow a uniform
recommendation.
3REVIEW OF LITERATURE
Hypertensive disorders complicate 5 to 10 per cent of all
pregnancies and together they form one member of a deadly triad,
along with hemorrhage and infection that contribute greatly to
maternal and prenatal morbidity and mortality rates.  How
pregnancy incites or aggravates hypertension remains unsolved
despite decades of intensive research.  Indeed, hypertensive
disorders remain among the most significant and intriguing
unsolved problems in obstetrics.
Terminology and Classification 1
Although many classification schemes have been proposed,
the scheme of the Working Group of the NHBPEP – National High
Blood Pressure Education Programme (2000) is widely followed.
The Working Group classification of hypertensive disorders
complicating pregnancy describes four types of hypertensive
disease:
1. Gestational hypertension
2. Preeclampsia and eclampsia syndrome
43. Preeclampsia syndrome superimposed on chronic
hypertension
4. Chronic hypertension
Hypertension
Hypertension is diagnosed empirically when appropriately
taken blood pressure exceeds 140 mm of Hg systolic or 90 mm of
Hg diastolic.  Korotkoft phase V is used to define the diastolic
pressure.  The incremental increase from mid pregnancy values by
30 mm of Hg systolic or 15 mm of Hg diastolic pressure used in the
past as a diagnostic criterion is no longer recommended because
recent evidence shows that such women are not likely to
experience increased adverse pregnancy outcomes 8, 9.
Proteinuria
Significant proteinuria is defined as the urinary excretion of
300 mg/l or more of proteinuria in a 24 hour urine collection or
persistent 30 mg/dl (1+) on dipstick testing for proteinuria in
random urine samples.
5Gestational hypertension
The diagnosis of gestational hypertension is made in women,
who develop non proteinuric hypertension after mid pregnancy, and
the blood pressure returns to normal by 12 weeks post partum and
the final diagnosis is made post partum.
Preeclampsia
The diagnosis of preeclampsia is made by the occurrence of
hypertension along with significant proteinuria after 20 weeks of
gestation on a previously normotensive and non proteinuric
pregnant woman.
Eclampsia
The onset of convulsions in women with preeclampsia that
cannot be attributed to other causes is termed eclampsia.
Superimposed preeclampsia on chronic hypertension
It is defined by the new onset proteinuria in a hypertensive
woman, but no proteinuria before 20 weeks of gestation or a
sudden increase in proteinuria or blood pressure or platelet count
6of less than 100,000/µl in a woman with hypertension and
proteinuria before two weeks of gestation.
Chronic Hypertension
A diagnosis of chronic hypertension complicating pregnancy
is made when there is a prepregnancy hypertension or
hypertension diagnosed before 20 weeks of gestation not
attributable to gestational trophoblastic disease or hypertension
diagnosed after 20 weeks of gestation, which persists after 12
weeks post partum.
Incidence and Predisposing Factors
Hypertension disorders of pregnancy complicate about 5 to
10 per cent of all pregnancies with 70 per cent of them gestational
hypertension, preeclampsia or eclampsia and 30 per cent being
chronic hypertension complicating pregnancy 6, 7.
The incidence is influenced by age, family and genetic
factors.
Preeclampsia is a disease of young primigravidae and
accordingly the incidence is higher in this group.  In one study,
7among 2434 singleton pregnancies, the incidence was 14.1 per
cent in primigravida versus 5.7 in multipara 10.
Preeclampsia is more likely to occur at both extremes of
reproductive age, but is greater in women younger than 20 years of
age.  The increased incidence in patients older than 35 years
probably reflects undiagnosed chronic hypertension with
superimposed preeclampsia.
Primipaternity is also believed to be a risk factor in
preeclampsia 11.  Unprotected sexual cohabitation for longer than
six months was found to decrease the risk of preeclampsia 11, 12.
The incidence was also increased in patients pregnant with
twins (13%) 13 and the incidence was unrelated to zygosity 14.
The incidence is also increased in patients who had
preeclampsia in previous pregnancy15, the probability of recurrence
being approximately 30 % and this increases in an inverse
relationship to the gestational age at which the patient developed
the disease.
8Other risk factors include pregestational diabetes, vascular or
connective tissue disease, nephropathy, antiphospholipid antibody
syndrome, obesity, and family history 16, 17.
Although smoking during pregnancy causes a variety of
adverse pregnancy outcomes, ironically, it has consistently been
associated with reduced risk of hypertension during pregnancy 18.
Preeclampsia
The minimum criteria for diagnosis of preeclampsia are new
onset of hypertension and proteinuria in a pregnant woman after 20
weeks of gestation.  The following are the indicators of the severe
preeclampsia 1:
1. Systolic blood pressure of ? 160 mm Hg or diastolic
blood pressure of ? 110 mm of Hg
2. Proteinuria of 5 g or higher in a 24 hour urine specimen
or 3+ or greater on dipstick testing of two random urine
samples collected at least  four hours apart.
3. Oliguria of less than 500 ml in 24 hours
4. Cerebral or visual disturbances
95. Pulmonary edema or cyanosis
6. Right upper quadrant or epigastric pain
7. Impaired liver function
8. Fetal growth restriction
9. Thrombocytopenia
Etiopathogenesis
The exact etiology of preeclampsia is unknown.  Several
theories have been proposed over the years, most of which have
not withstood the test of time.  Some of these failed to stand to
further investigations, while others yielded conflicting results in
different studies, and none could explain all the changes in this
condition.  As Boyd stated preeclampsia remains “die krankheit der
theorien” – the disease of theories 4.
Some of the currently considered factors in the causation of
preeclampsia are:
1 Abnormal placentation
In preeclampsia, there is an incomplete trophoblastic invasion
of the uterine spiral arterioles resulting in a smaller vessel caliber
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with a high resistance to flow.  It is likely that the abnormally narrow
arterioles impair the placental blood flow.  Diminished perfusion
and a hypoxic environment eventually lead to release of placental
debris that incites a systemic inflammatory response.
2 Endothelial dysfunction
Endothelial dysfunction is a central feature in preeclampsia
resulting in activation of coagulation cascade and loss of vascular
integrity.  Biomarkers of endothelial dysfunction such as plasma
fibronectin and thrombomodulin are elevated in preeclamptic
pregnancies even before the clinical syndrome manifests,
suggesting that endothelial abnormalities are the cause of
preeclampsia and not its effect 19.
3 Immunological factors
Loss or dysregulation of maternal immune tolerance to
paternally derived placental and fetal antigens is another theory
cited to account for the preeclamptic syndrome.  Certainly the
histological changes at the maternal placental interface are
suggestive of acute graft rejection 20.  There are inferential data
that suggest an immune mediated disorder, which include:
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i. The risk of preeclampsia is appreciably enhanced in
circumstances in which formation of blocking autoantibodies
to placental antigenic sites might be impaired.  In this
scenario, the first pregnancy would carry a higher risk 21.
ii. Tolerance dysfunction might also explain an increased risk
when the placental antigenic load is increased, that is, with
two sets of paternal chromosomes – “a double dose”.  For
example molar pregnancies have a higher incidence of
preeclampsia.
iii. Conversely, women previously exposed to paternal antigens,
such as a prior pregnancy with the same but not different
partner are immunized against preeclampsia 11,12.
4 Genetic predisposition
A variety of genetic associations to preeclampsia have been
recognized.  The incident risk of preeclampsia is 20 - 40 % for
daughters of preeclamptic women, 11 – 17 % for sisters of
preeclamptic women and 22 – 47 % in twins 22.  The hereditary
predisposition likely is the result of interactions of literally hundreds
of inherited genes – both maternal and paternal.  More than 70
12
genes have been studied for their possible association with
preeclampsia.  Seven of these have been widely investigated and
are listed below.
Genes Frequently Studied for their Association with
Preeclampsia Syndrome
Gene
(polymorphism)
Function
affected
Chromosome Biological
Association
MTHFR (677T) Methyl
tetrahydro-folate
reductase
1p 36 – 3 Vascular
disease
F 5 (Leiden) Factor V Leiden 1 q 2 3 Thrombophilia -
may coexist
with other
thrombophilic
genes
AGT (M 235 T) Angiotensinogen 1 q 42 – q 43 Blood pressure
regulation,
linked to
essential
hypertension
HLA (various) Human
leukocyte
antigen
6 p 21. 3 Immunity
13
Gene
(polymorphism)
Function
affected
Chromosome Biological
Association
N O S 3
(Glu 298 Asp)
Endothelial nitric
oxide
7q 3 6 Vascular
endothelial
function
F 2 (G20210 A) Prothrombin
(Factor II)
11 p 11 q –
12
Coagulation –
weakly
associated,
studied with
other
thrombophilic
genes
ACE
(I / Dat Intron
16)
Angiotensin
converting
enzyme
17q 2 3 Blood pressure
regulation
Adapted from Ward and Lindheimer, 2009 22
5 Oxidative stress
Although there is growing evidence indicating the increased
risk of preeclampsia in women with elevated levels of oxidized low
density lipoproteins and triglycerides, the causal relations of lipid
peroxidation in the pathogenesis of preeclampsia is not clear.
Cytokines like tumour necrosis factor ?, and the interleukins may
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contribute to oxidative stress associated with preeclampsia.  This is
characterized by reactive oxygen species and free radicals that
lead to the formation of self propagating lipid peroxides.  These in
turn generate highly toxic radicals that injure endothelial cells,
modify their nitric oxide production, and interfere with prostaglandin
balance 23.
The observations on the effect of oxidative stress on
preeclampsia have given rise to increased interest on the potential
benefits of antioxidants to prevent preeclampsia.  However, dietary
supplementation with the antioxidants to prevent preeclampsia has,
thus far proven unsuccessful.
6 Role of vasoactive agents
1) Renin – Angiotensin – Aldosterone System
In normal pregnancy, all the elements of this system, i.e.
renin activity, plasma renin concentration, and angiotensin II levels
increase.  However the pregnant woman displays reduced
responsiveness to the effects of angiotensin II 24.
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In preeclampsia, plasma renin activity and angiotensin II
levels are usually lower than normal throughout the pregnancy.  In
addition, the refractoriness to angiotensin II is lost as early as mid-
trimester in women who are destined to develop preeclampsia 24,25.
2) Protaglandins
A number of prostanoids are thought to be central to the
pathophysiology of the preeclampsia syndrome.  There is evidence
that compared to normal pregnancies, there is an increase in
thromboxane A2 production and a decrease in prostacyclin (PG I2)
resulting in vasoconstriction.
3) Nitric oxide
Nitric oxide is a potent vasodialator produced by the
endothelial cells and is the likely compound that maintains the
normal low pressure vasodialated state characteristic of the
uteroplacental perfusion.  The effects of nitric oxide production in
preeclampsia are unclear 26,27.  It appears that the syndrome is
associated with decreased endothelial nitric oxide synthase
expression.
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4) Endothelins
Endothelins are potent vasoconstrictors and Endothelin - I is
the primary isoform produced by the human endothelium and its
levels are increased in preeclampsia 27.
Pathophysiology
Although the cause of preeclampsia still remains unknown,
evidence for its manifestation begins early in pregnancy with covert
pathophysiological changes that gain momentum across gestation
and eventually become clinically apparent.
1 Cardiovascular system
1) Hemodynamic changes
i. Increased cardiac afterload caused by hypertension
ii. Reduced preload as a result of pathologically diminished
hypervolemia of pregnancy during preeclampsia
iii. Decreased cardiac output
17
iv. Endothelial activation with extravasation of intravascular
fluid into extravascular space
2) Blood volume
 Hemoconcentration is the hallmark of preeclampsia.
2 Hematological system
1)  Thrombocytopenia – It is the most commonly identified
hematological abnormality in women with preeclampsia.
Overt thrombocytopenia- defined by a platelet count of less
than 100,000/µl indicates severe disease.  After delivery it
will usually reach normal level in 3 to 5 days.
2) Hemolysis – severe preeclampsia is frequently accompanied
by evidence of hemolysis, which is semiquantified by
elevated serum lactate dehydrogenase levels.
3) HELLP syndrome - In addition to hemolysis and
thrombocytopenia, it has also become appreciated that
elevated serum hepatic transaminase levels were commonly
found with severe preeclampsia and were indicators of
18
hepatocellular necrosis.  Weinstein (1992) referred to this
combination of events as HELLP syndrome 28.
4) Coagulation – Subtle changes consistent with intravascular
coagulation are commonly found in preeclampsia and
superimposed preeclampsia 29. Some of these changes
include:
i. Increased Factor VIII consumption
ii. Increased levels of fibrinopeptide and fibrin degradation
products
iii. Decreased levels of regulatory proteins – Antithrombin III
and protein C and S
iv. Unless complicated by abruption, plasma fibrinogen levels
do not differ remarkably from levels found in normal
pregnancy.
5)   Other clotting factors
i. Thrombophilias are clotting factor deficiencies that lend to
hypercoagulability and may be associated with early onset
preeclampsia 30.
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ii. Fibronectin, a glycoprotein associated with vascular
endothelial cell basement membrane is elevated in women
with preeclampsia, consistent with endothelial injury
3.  Volume Homeostasis
1) Endocrine changes
i. Plasma levels of renin, angiotensin II and aldosterone
levels decrease substantially with preeclampsia despite
decreased blood volume
ii. Vasopressin levels are similar to that in normal pregnant
women
iii. Secretion of atrial natriuretic peptide is decreased in
women with preeclampsia
2) Fluid and electrolyte changes
i. In women with severe preeclampsia, the volume of extra
cellular fluid, manifesting as edema, is usually greater than
that of normal pregnant woman
20
ii. Electrolyte concentrations do not doffer appreciably in
women with preeclampsia compared with that of normal
pregnant  women
4. Kidney
1) Reduced renal perfusion and hence a reduced glomerular
filtration rate, probably as a result of increased renal afferent
arteriolar resistance 31.
2) Serum creatinine may rise to values seen in non pregnant
individuals, i.e. 1 mg/dl.
3) Plasma serum uric acid concentration is typically elevated in
preeclampsia, probably as a result of reduction in glomerular
filtration rate and due to enhanced tubular reabsorption 32.
4) Proteinuria which is non selective and is due to endothelial
injury in the glomeruli.
5) Preeclampsia is associated with hypocalciuria as a result of
result of increased tubular reabsorption 33.
6) Anatomical changes – Glomeruli are diffusely enlarged and
are avascular termed as ‘Glomerular capillary endotheliosis’.
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7) Rarely, acute renal failure as a result of acute tubular
necrosis may be caused by preeclampsia.
5 Liver
1) Anatomical changes – Subscapular hemorrhages and rarely
rupture can occur in preeclampsia.  The characteristic lesions
are  periportal hemorrhages in the periphery of liver.
2) Elevated serum hepatic transaminase levels which along with
hemolysis and thrombocytopenia constitute the HELLP
syndrome 28.
6 Brain
Brain may show multiple petechial hemorrhages or larger
hemorrhages in the cortex, pons or midbrain.  The classical
microscopic vascular lesions consist of fibrinoid necrosis of
the arterial wall and perivascular microinfarcts and
hemorrhages.
7 Visual changes and blindness
Scotomata, blurred vision or diplopia are common with
severe preeclampsia or eclampsia.  Blindness usually
22
reversible and may arise from three potential regions – visual
cortex, lateral geniculate body or retina (ischaemia,
infarctation or retinal detachment).
Proteinuria
In non pregnant women, daily urine protein excretion
averages 20 – 80 mg/day (with an upper limit of 150mg/day).  This
is 40 % albumin, 15 – 20 % immunoglobulin (IgG – 5 – 10 %,
IgA – 3 % and light chains 5 – 10 %) and remainder is Tamm-
Horsfall glycoprotein derived from the tubules and the lower urinary
tract 34.
The movement of proteins across the capillary walls in the
glomeruli is influenced by the protein size, configuration and
charge.
Renal handling of proteins in normal pregnancy
In pregnancy, the renal hemodynamic changes mean that
greater quantities of colloids and solute pass by the glomerular
barrier per unit time.  In addition, there are changes in glomerular
permeability and altered tubular reabsorption of filtered proteins
that may result in increased excretion of protein.  The currently
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accepted upper limit of normal is 300 mg/24 hours for total protein
excretion 35.
Altered tubular reabsorption in pregnancy can be
demonstrated by measuring urinary excretion of low molecular
weight proteins which have identical plasma concentration in non
pregnant and pregnant women and are freely filtered by
glomerulus.  These proteins, including Retinal Binding Protein, ?-2
microglobulin and ? - 1 microglobulin, have been compared with
albumin whose excretion is affected by the size and charge
permselectivity of the glomerular barrier.  Their increased excretion
in uncomplicated pregnancy is due to their reduced reabsorption in
the proximal tubule 36.
Renal handling of proteins in preeclampsia
Most classification systems for the hypertensive disorders of
pregnancy have placed emphasis on the appearance and
progression of proteinuria above a threshold of 300 mg/24 hours to
separate gestational hypertension from preeclampsia.  This
threshold, therefore defines significant proteinuria.
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In preeclampsia, the glomerular barrier is certainly altered
and there is increased excretion of proteins including albumin.
When the total protein excretion exceeds 1.0 g/24 hours, the
tubular protein reabsorption will be saturated and individual protein
excretion rates will be related to their molecular weights.  The term
selective proteinuria is used when large protein molecules are
retained and non selective proteinuria is used when the glomerular
barrier looses this ability.  In preeclampsia, the proteinuria is
considered to be nonselective 37.
The incidence of proteinuria in most populations is about 10
per cent in all pregnant women.  Proteinuria can be caused by
pregnancy itself, or may exist from before conception.  However, as
pregnancy may be the first point of contact, preexisting proteinuria
may be first diagnosed at this time.  Although less prevalent,
primary renal disease or renal disease secondary to systemic
disorders such as diabetes or essential hypertension may present
with proteinuria in pregnancy.
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Proteinuria and clinical outcome
Hypertension with proteinuria is clearly associated with
increased fetal and maternal mortality, especially if occurring
remote from term 38,39,40,41.  In contrast women with mild
hypertension without proteinuria have similar outcomes to non-
hypertensive women.  But, if chronic hypertension is complicated
by the development of proteinuria, there is 10 % incidence of
placental abruption, a 33 % incidence of growth restriction and a
perinatal mortality of up to 24 % 42.
Page et al. in a prospective study of almost 13,000 pregnant
women, found that significant proteinuria was associated with an
increase in still birth rates, fetal growth restriction and neonatal
morbidity, when associated with hypertension 43.
Ferrazzani et al. studying a group of 444 hypertensive
women pregnancies where proteinuria was defined as ? 1+ by
dipstick or ? 0.3g/l, noted higher serum uric acid levels, lower birth
weights and birth percentiles, and more deliveries before 37 weeks
of gestation, if hypertension was associated with proteinuria 42.
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Chua and Kidman have reported that when the level of
proteinuria exceeds 5 g/24 hours, delivery is usually required within
2 – 3 weeks 44.
There is no evidence to suggest an adverse maternal or fetal
outcome in relation to the degree of proteinuria and hence it is the
presence of proteinuria that confers increased maternal and
perinatal morbidity, not necessarily its severity 9.
In a study by Waugh et al. among 197 pregnant women, it
was found that the threshold of 300 mg/24 hours was not predictive
of the adverse outcome.  They concluded that though 300 mg/24
hours may be above the 95th centile for an obstetric population, it is
the threshold of 500 mg/24 hours that is more predictive of an
adverse outcome 45.
Assessment of proteinuria
All pregnant women are routinely screened for proteinuria at
their first visit and at regular intervals thereafter by heat coagulation
test or dipstick test.  If the test is negative, clinically significant
proteinuria is precluded; but if it is positive, further investigation is
necessary.
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Heat coagulation test
It is done by adding 3 – 4 drops of acetic acid to the urine
after heating.  Results are graded depending on the turbidity and
hence are subjective.  They are associated with a number of false
positive and false negative results 3.
Dipstick test
This test is carried out on the first morning specimen of urine,
preferably because it tends to be more concentrated and is not
affected by postural factors.  The dipsticks are more sensitive to
albumin than other plasma proteins.
The reactive portion of the stick is coated with a buffered
indicator that changes colour in the presence of protein and the test
is read after 60 seconds.  It is graded as follows 5:
Trace - 0.1 g/l
1+ - 0.3 g/l
2+ - 1 g/l
3+ - 3 g/l
4+ - 10 g/l
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Dipstick testing is, however, associated with a large number
of false positives which can be due to a very concentrated
specimen (specific gravity of more than 1.030), alkaline urine,
contamination with antiseptics like chlorhexidine or quaternary
ammonium compounds or vaginal discharge.  False negative
results can also occur due to very dilute urine (specific gravity of
less than 1.010) 3.
Quantitative assay of proteinuria
Persistent dipstick proteinuria requires further evaluation.
Quantitative assay for total proteins excretion is usually performed
on timed collections, usually a 24 hour urine specimen.
24 hour urine collection
The 24 hour urine collection for estimation of proteinuria is
the gold standard in diagnosis of proteinuria in preeclampsia.
Though a reliable indicator of proteinuria, it has the disadvantage of
being a cumbersome and time consuming process, subject to
collection error and requires patient compliance.  Further, there is a
delay of 24 hours from the time of collection till the diagnosis is
made.
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Dipstick urinalysis and 24 hour urinary protein excretion
The primary reason for the dependence upon the dipstick test
is the relative low cost and ease with which it can be performed.  It
is a widely held belief that 1+ proteinuria by dipstick corresponds to
300 mg/24 hours total protein excretion.  There are several studies
which investigated the relationship between semiquantitative
dipstick urine analysis on random voided urine samples and a
subsequently collected 24 hour urine sample.
In a study by Meyer et al. among 300 hypertensive women,
66 % of the women had false negative dipstick urinalysis, if
significant proteinuria was defined as ? 300 mg/24 hours.  In the
same series they reported a false positive rate of 26 % at the 1+
level 46.
In a study, Brown et al. reported a false negative result of 8 –
18 % and a very high false positive rate of 67 % with 1+ score.
They suggested that the dipstick is too sensitive at the 1+ threshold
and that as such it is useful for the management of preeclampsia
as it will minimize the false negative results (missed proteinuria),
but the test will be incorrect at least half of the time 67.
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Waugh et al.’s data on 197 hypertensive women, found a
high false negative rate of up to 65 % in women with < 1+
proteinuria on dipstick analysis, but had significant proteinuria 47.
All these suggest that the correlation between dipstick
urinalysis and 24 hour protein estimation is at best imprecise.
False positive results may result in over investigation and
intervention whereas the potentially more serious issue of false
negative result may place a woman and her pregnancy at risk.
The review of literature thus shows that the accuracy of
dipstick urinalysis using a threshold in the prediction of significant
proteinuria is poor.  It is, however, not possible for dipstick
urinalysis to be removed from antenatal care without a viable
alternative test to replace it.
Protein to creatinine ratio in spot urine samples
Measurements on random urine samples of the protein to
creatinine ratio have been reported to show a good correlation with
subsequent 24 hour urine protein estimation in non pregnant
populations (renal impairment 48, kidney transplants 49 and
diabetes50).  There has also been good evidence of a strong
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correlation between random sample protein to creatinine estimation
and subsequent 24 hour protein excretion in hypertensive pregnant
population.
In the presence of a stable renal function test, a protein to
creatinine ratio of < 0.2 is said to be within normal limits and a
protein to creatinine ratio of > 3.5 represents nephrotic range of
proteinuria.  Studies reasoned out that the ratio of two stable
excretion rates (protein and creatinine) minimize the time involved,
thus providing a faster estimate of 24 hour protein excretion 51,52.
Leanos-Miranda et al. from their cross-sectional study of 927
hospitalised pregnant women with suspected preeclampsia and
161 pregnant women in whom hypertensive disorders of pregnancy
was ruled out for comparison, found that the protein to creatinine
ratio and the 24 hour protein excretion were significantly correlated
( r = 0.98 , p < 0.001 ).  The protein to creatinine ratio as an
indicator of protein excretion of ? 300 mg/24 hours was ? 0.3.  The
sensitivity and specificity were 98.2% and 98.8% respectively.  The
positive and negative predictive values were 97.2% and 99.2%.
They concluded that protein to creatinine ratio may be reasonably
used as an alternative to the 24 hour urine collection method 53.
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In a study by Shahbazian et al. among 81 pregnant women
with preeclampsia, there was a strong correlation between the spot
protein to creatinine ratio and 24 hour urine protein excretion (r =
0.84, p < 0.001).  The optimal spot protein to creatinine ratio cut off
point was 0.20 for 300 mg/24 hours of protein excretion, with a
sensitivity, specificity, positive predictive value and negative
predictive value of 91.2 %, 87.8 %, 94.4 % and 96.8 %,
respectively.  The value of less than 0.19 yielded a sensitivity of
100 % for exclusion of preeclampsia 54.
In another study by Nisell et al., there was a close correlation
between the albumin to creatinine ratio and 24 hour albumin
excretion values (r = 0.95, p < 0.001) and they concluded that in
most cases, the more cumbersome 24 hour urine collection can be
replaced by the more convenient albumin to creatinine ratio on the
spot urine 55.
Papanna and colleagues in a systematic review, concluded
that the random urine protein to creatinine ratio determinations are
helpful primarily when they are below 130 – 150 mg/g, in that 300
mg or more proteinuria is unlikely below this threshold.  Midrange
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protein to creatinine ratio (300 mg/g) had poor sensitivity and
specificity, requiring a full 24 hour urine for accurate results 56.
In a study by Wheeler et al., though random spot urine
protein to creatinine ratio was strongly correlated with the 24 hour
urine protein levels (r = 0.88), it was concluded that the use of spot
protein to creatinine ratio was not justified as a substitute for timed
collection 57.
In a systematic review, Cote et al. concluded that the spot
protein to creatinine ratio is a reasonable “rule out’’ test for
detecting proteinuria of 0.3 g/day or more in hypertensive
pregnancy 58.
Durnwald and Mercer in their study among 220 women found
a poor correlation between the spot urine protein to creatinine ratio
and 24 hour urine protein (r2 = 0.41) and they concluded that
protein to creatinine ratio does not exclude adequately the
presence of significant proteinuria or predict severe proteinuria and
should not be used as an alternative to 24 hour total protein
excretion 59.
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So the clinical utility of urine protein to creatinine ratio as a
substitute of 24 hour urine protein excretion for detecting significant
proteinuria still remains unclear.  Though some investigators have
proposed the use of spot urine protein to creatinine ratio, there are
also reports with conflicting results.
In this study, the correlation between the spot urine protein to
creatinine ratio and 24 hour urine protein excretion in patients
being evaluated for preeclampsia has been studied.
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AIM OF THE STUDY
1. To study the correlation between the spot protein to
creatinine ratio of a single random sample and 24 hour urine
protein excretion in women admitted for evaluation of
preeclampsia.
2. To know if spot protein to creatinine ratio would provide
accurate quantification of proteinuria in preeclampsia.
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MATERIALS AND METHODS
Study period : December 2009 to November 2010
Sample size : 150
Study design : Prospective study
Source of data
One hundred and fifty pregnant women who were admitted
for evaluation of preeclampsia were studied prospectively after
getting informed written consent.  The study was conducted at the
Department of Obstetrics & Gynaecology at Govt. R.S.R.M.
Lying-in Hospital attached to Stanley Medical College, after getting
approval from the Hospital Ethical Committee.
Selection criteria
Inclusion criterion
Pregnant women with preeclampsia, with preeclampsia being
defined as systolic blood pressure of ? 140 mm Hg or diastolic
blood pressure of ? 90 mm Hg on at least two occasions 6 hours
apart , accompanied by a proteinuria of ? + 1 as detected by
dipstick test, after 20 weeks of gestation.
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Patients were categorized as severe preeclampsia, if any of
the following criteria are met:
Systolic BP ? 160 mm Hg
Diastolic BP ? 110 mm Hg
Proteinuria of 5 g/24hours or more or persistent 3+ by Dipstick
Oliguria (24 hour urine output < 500 ml)
Cerebral / Visual disturbances
Pulmonary edema
Epigastric / Upper right quadrant pain
Impaired liver function
Thrombocytopenia
IUGR
Elevated serum creatinine level
Exclusion criteria
1. Pre-existing renal disorder – A stable renal function was
ascertained by doing Blood urea and Serum creatinine
2. Urinary tract infections – Urine analysis was done for all
patients to exclude the presence of microscopic hematuria,
casts and bacteriuria.
3. Chronic hypertension
4. Gestational diabetes
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5. In addition, woman who delivered their babies during the day
of urine collection were excluded.
Procedure
One hundred and fifty patients who satisfied the above
criteria were recruited for the study.  Informed written consent was
obtained from all the patients.
1. A detailed history was taken.
2. General physical and systemic examination was done.
3. The blood pressure was measured with an appropriate size
cuff with the patient in an upright position after at least 10
minutes rest.  Diastolic BP was determined as the
disappearance of sound (Korotkoff Phase V).
4. Complete obstetric examination was done.  Per speculum
examinations were done to look for any evidence of vaginal
infection clinically.
5. Urine microscopy was done to rule out the presence of
infection.
6. Proteinuria was assessed in a random sample of urine by the
dipstick method.  Proteinuria by the dipstick method was
graded as follows:
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Trace 0.1 g/l
1 + 0.3 g/l
2 + 1 g/l
3 + 3 g/l
4 + 10 g/l
If the dipstick test showed proteinuria of 1+ or more,
quantitative tests for proteinuria were carried out.
7. Spot urine protein – creatinine ratio
A spot midstream sample of urine was collected from all the
patients, immediately prior to the beginning of the collection
for 24 hour urine protein estimation.  The samples were sent
to the Biochemistry laboratory where
a) Urine protein was measured by the sulphosalicylic acid
method
b) Urine creatinine was estimated by Modified Jaffe’s method
c) The urine protein and creatinine ratio was obtained by
dividing the urine protein concentration (in mg/dl) by the
urine creatinine concentration (in mg/dl)
8. Urine samples were collected for 24 hours (after collecting
the specimen for spot test) and the urinary protein excretion
in 24 hours was estimated.
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9. Normal values for protein excretion
24 hours urine protein (in mg/24 hours)
Not significant < 300
Clinically significant > 300
Severe proteinuria > 5000
Protein creatinine ratio
Not significant < 0.2
Clinically significant ? 0.20
10. Hemoglobin (g/dl), Platelet count, Blood urea, serum
creatinine and liver function test (Sr. bilirubin, Sr. proteins
(total and albumin), SGOT & SGPT, LDH) were done for all
patients.
11. Fundus examination was done for all patients
12. USG and Doppler study was done wherever indicated
(suspicion of IUGR)
13. The data thus collected were analyzed using appropriate
statistical methods.  Descriptive statistics were used for
demographic and baseline data and summarized as mean +
S.D., median and percentage, wherever appropriate.
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14. The relationship between the urine protein creatinine ratio
and 24 hour protein excretion was assessed with Pearson’s
correlation test and correlation coefficient was calculated
which is expressed as “r”.
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RESULTS AND ANALYSIS
Table I :  Age distribution of subjects
Age
(years)
Mild
preeclampsia
Severe
preeclampsia
Total
<  20 20
(13.33)
15
(10)
35
(23.33)
21 – 30 68
(45.33)
30
(20)
98
(65.33)
> 30 7
(4.67)
10
(6.67)
17
(11.33)
Total 95
(63.33)
55
(36.67)
150
(100)
Figures in parentheses indicate percentage
In this study, it was noticed that majority (65.33 %) of the 150
subjects studied were in the age group of 21 – 30 years (Fig. 1).
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Fig. 1  Age distribution of subjects with mild and severe
preeclampsia
Mild
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Table II:  Distribution of preeclampsia among subjects
Preeclampsia Frequency Per cent
Mild 95 63.33
Severe 55 36.67
Total 150 100
It was noticed in this study that of the 150 subjects studied,
63.33% were having mild preeclampsia and 36.67% had severe
preeclampsia (Fig. 2).
63%
37%
Fig. 2  Pie chart showing distribution of
preeclampsia among subjects
Mild Severe
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Table III:  Paritywise distribution of subjects
Gravida
Preeclampsia
Total
Mild Severe
Primi 49 (32.67) 37 (24.67)  86 (57.33)
Multi 46 (30.67) 18 (12.00)  64 (42.67)
Total 95 (63.33) 55 (36.67) 150 (100)
Figures in parentheses indicate percentage
It is observed in this study that the incidence of pre-eclampsia
in primigravida was 57.33% and multigravida was 42.67% (Fig. 3).
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Fig. 3 Paritywise distribution of subjects
Primi Multi
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Table IV:  Distribution of subjects as per gestational age
Gestational
age (wks.)
Preeclampsia
Total
Mild Severe
20 – 28 weeks   6 (4.00)   5 (3.33) 11 (7.33)
28 – 36 weeks 47 (31.33) 33 (22.00) 80 (53.33)
? 37 weeks 42 (28.00) 17 (11.33) 59 (39.33)
Total 95 (63.33) 55 (36.67) 150 (100)
Figures in parentheses indicate percentage
It was observed that, out of 150 subjects majority (53.33 %)
were between 28 – 36 weeks.  Severe preeclampsia was also
found to be most common in this group accounting for 33 of 55
(60%) severe cases (Fig. 4).
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Fig. 4  Distribution of subjects as per gestational age
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Table V:  Summary statistics of different parameters*
Variables Mean SD SE Minimum Maximum
Age in
years 24.20 4.75 0.388 18 37
POG in
weeks 34.62 3.69 0.301 24 40
Sys. BP
in mm of
Hg
144.95 9.65 0.788 130 170
Dia. BP
in mm of
Hg
93.99 7.63 0.623 80 110
24 hours
urine
protein in
mg/day
925.02 1077.28 87.39 132 7800
Protein
creatinine
ratio
1.52 1.46 0.119 0.13 11.39
* The number of subjects is 150
Box plot analysis showed that values with more than 2000
mg/24 hour urine extraction were outliers (Fig. 5).
Box plot analysis also showed that spot protein creatinine
ratios above 2.5 are extreme values (Fig. 6).
Fig. 5. Box plot showing 24 hour urine protein excretion
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Table VI:  Comparison of urinary dipstick against 24 hours
urine protein
Dipstick
24 hours urine protein (mg/day)
Total
< 300 300 - 2000 >2000
1 + 29 66 - 95
2 + 2 33 1 36
3 + - 6 9 15
4 + - 2 2 4
Total 31 107 12 150
The box plot analysis of 24 hour urine protein extraction at
different dipstick readings (Fig. 7) showed that at dipstick readings
at 1+ and 4+ the median line is almost in the centre of the box,
indicating more or less normal distribution of these values.
However at the dipstick values of 2+ and 3+ there is a skewed
distribution.
Fig. 7. Box plot analysis of 24 hour urine protein excretion
at different dipstick values
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Table VII :  Comparison of urinary dipstick against protein
creatinine ratio
P/C ratio Dipstick Total
1 + 2 + 3 + 4 +
< 0.2 12 1 - - 13
? 0.2 83 35 15 4 137
Total 95 36 15 4 150
The box plot analysis of spot protein creatinine ratio at
different dipstick readings (Fig. 8) showed that the distribution of
spot protein creatinine ratios is skewed at all dipstick readings and
more values were in the upper quartile of the median.  However the
degree of skewness was less in the dipstick value of 1+.
Fig. 8. Box plot analysis spot protein creatinine ratio
at different dipstick values
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Table VIII :  Comparison of 24 hour urine protein and spot
urine protein creatinine ratio
Spot PCR
24 hours urine protein mg/day
Total
< 300 300 – 2000 > 2000
< 0.2 13 2 - 15
? 0.2 18 105 12 135
Total 31 107 12 150
Correlation coefficient between protein/creatinine ratio and 24
hour urinary protein
Karl Pearson’s
correlation between
Correlation
coefficient “r”
P value
PCR and 24 hours
urine protein
0.756 0.01
A fair correlation of r = 0.756 was observed between the 24
hours urine protein and spot urine protein-creatinine ratio among
the 150 subjects, which was significant at a P value of < 0.01.
The scatter plot shown in Figure 9 indicates a good linear
relationship between the two variables.
Fig.9. Scatter plot showing the distribution of 24 hour
urine protein (mg) and spot urine protein creatinine ratio
(all values)
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When only the data for 24 hours urine protein < 2000 is
analyzed, the simple linear correlation between 24 hours urine
protein and spot urine protein creatinine ratio a shows better linear
relationship (Fig. 10) and the “r” value is 0.914 which is highly
significant at 0.001 probability level.  This is also illustrated by the
Figure 11 showing linear and quadratic relationship between spot
urine protein ratio and 24 hour urine protein as well as the
observed values.
The linear relationship of 24 hour UP (y) on SPCRATIO (x) is
given by the following relationship:
a. 24 hour UP = 206.58 + 509.42 * SPCRATIO with a high
coefficient of determination (83%)
b. The Students’ t-test indicates that the regression
coefficient is highly significant (P=0.01)
c. The estimated coefficients of the above model can be
expressed as:
Constant ‘a’ =  206.58 ± 21.10
Regr.Coeff ‘b’  =  509.42 ± 19.40,
where the values after the operator ± are Standard
Errors of the respective coefficients
Fig. 10.  Scatter plot showing the distribution of 24 hour urine protein
and spot urine protein creatinine ratio
(for 24 hour urine protein values < 2000)
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The graphical presentation of the linear model fit is shown in
the following figure (green line).  A quadratic model fit is also
shown (the red colored curve).  Since the quadratic model does not
give appreciable increase in coefficient of determination (R2), the
linear model is sufficient for all practical purposes.
For a given value of X (Spot protein creatinine ratio), the Y
(24 hour urine protein extraction) value can be estimated from the
equation (a) above, so also for a given Y (24 hour urine protein
extraction), the corresponding projection on X can be estimated.
So for a value of 24 hour urine protein extraction = 300, the Spot
protein creatinine ratio is estimated to be: 0.1834.
            With the protein creatinine ratio of 0.2 taken as the
threshold to detect significant proteinuria, the sensitivity and
specificity were 100% and 45% respectively and the positive and
negative predictive value were 86.9% and 100% respectively.
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DISCUSSION
Measurement of proteinuria is one of the most routinely
undertaken laboratory procedures.  It is mandatory in evaluating
women with hypertensive disorders of pregnancy, and is necessary
to establish the diagnosis of preeclampsia, as well as its severity.
Urinary protein excretion during a 24 hour period, however, is
considered to be cumbersome and subject to error due to
inadequate collection.
This study was conducted to evaluate the correlation
between 24 hour urine protein excretion and spot protein creatinine
ratio on random urine samples and to determine its accuracy.
A rapid and accurate test may avoid the inconvenience for the
patient and will also avoid the delay in diagnosis and management.
This study was limited to the hospitalised nonambulatory
patients.  Since the protein excretion is affected by postural
changes, being higher in the standing than in supine position, the
ambulatory status of the patient is important while interpreting the
results.
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In this study of 150 preeclamptic women, the socio-
demographic variables shows that the peak age range was 21 - 30
years with the mean age being 24.20 years.  The peak age of
21 – 30 years may be reflective of the fact that most first deliveries
in this environment occur at that age and not necessarily of any
special contribution of this age bracket to the etiology of the
disease.
This study included a large number of patients with mild
preeclampsia (63.33%).  Primigravidae contributed the commonest
parity (57.33 %).  Primigravidae have been demonstrated by
numerous workers to be at high risk of developing preeclampsia.
The mean gestational age of the patients under study was 34.62
weeks.
We found a fair correlation in our study, when the 24 hour
urine protein and the random urine protein creatinine ratios were
correlated, with correlation relation coefficient, r = 0.756 and p
value being significant at < 0.01, when all the observations were
considered.
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The correlation was better at r = 0.914 and p < 0.001, for
lesser degrees of proteinuria i.e. < 2000 mg/24 hours.  But when
the correlation was computed for higher degrees of proteinuria i.e.
> 2000 mg/24 hours, there was very poor correlation, r – negative,
and not statistically significant.
Boler and associates studied the two parameters in 54
patients.  Excellent correlation was achieved (r = 0.9935, p <0.001)
between the two, and this was achieved for normal pregnancies,
hypertensive pregnancies and multiple gestation.  They however
did not specify the number of patients with preeclampsia.  In
patients with proteinuria of more than 1 g/24 hours, there were
variations in the results 62.  Similarly, the study conducted by
Jaschevatzky and associates on 35 preeclamptic patients and 70
healthy patients found close correlation (r = 0.9278, p < 0.001)
between 24 hour proteinuria and random urinary protein creatinine
ratio.  However, in patients with proteinuria greater than 2 g, the
degree of correlation decreased 65.  In both the studies, the sample
size was smaller than in this study, and predictive values of the
tests were not available.
55
In a study by Torng et al in 2001 to determine whether urine
protein/creatinine ratio can be used as a predictor for 24 hour
protein excretion in transplant patients, a good correlation could be
established between the two variables at 0.5 – 2.0 g/day of
proteinuria.  But the precision and positive predictive value
decreased as proteinuria increased >3g/day 68.
This variation in the results at severe degrees of proteinuria
indicates the need for careful interpretation of the results especially
when clinical decisions are to be based on them.
Out of 150 patients, 12 patients had proteinuria greater than
2 g/24 hours and only 3 patients had proteinuria of greater than
5 g/24 hours, which is an inadequacy of this study.  A poor degree
of correlation at severe degrees of proteinuria could probably be
due to the low prevalence of subjects with this range of proteinuria.
Since the present study included women only with a stable
renal function, our study supports the use of the protein/creatinine
ratio in women with normal renal function.
But Robert et al 61 in 1997 and Quadri et al 51 in 1994 have
proved in their studies that the protein/creatinine ratios are
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independent of renal function and reliable even in the presence of
underlying renal disease and have advocated their use to monitor
renal function in pregnancy.
Given below is a table which shows the results of some
similar studies in comparison with the present study.
Studies CorrelationCoefficient (r) p-value
Nisell et al. 55 0.95 < 0.001
Yamasmit et al.60 0.929 < 0.001
Robert et al. 61 0.94 < 0.001
Boler et al. 62 0.99 < 0.001
Rodriguez - Thompson et al.63 0.80 < 0.001
Young et al. 64 0.80 < 0.001
Jaschevatzky et al.65 0.92 < 0.001
Shahbazian et al. 54 0.84 < 0.001
Bansal et al.66 0.83 =0.000
Present study 0.756 <0.01
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Research in future should be focused on the evaluation of
clinical outcomes and the cost effectiveness of the use of a random
urinary protein creatinine ratio for prediction of significant
proteinuria.  In addition, studying the test in an outpatient basis
should be further considered in order to apply it in ambulatory
management of preeclamptic patient.  We suggest the test be done
also in severely preeclamptic women, as they tend to excrete
greater amounts of protein, in order to determine a cutoff value for
prediction of the 24 hour protein excretion greater than 5 g.
58
SUMMARY
The objective of the study was to know if a spot
protein/creatinine ratio would provide an accurate quantification of
proteinuria and whether it can replace the use of the 24 hour urine
protein in preeclamptic women.
One hundred and fifty women with pre-eclampsia were
recruited for the study.  A stable renal function was ascertained by
estimating serum creatinine and blood urea levels.  The patients
were instructed to collect the 24 hour urine starting from the second
urine sample in the morning till the first urine sample the next day
morning.  A single voided urine specimen was obtained before the
start of 24 hour collection for determination of the protein/creatinine
ratio.  The urine protein was measured using sulphosalicylic acid
method.  Urine creatinine was measured using modification of
Jaffe’s reaction which is commonly used to estimate creatinine.
Urine protein (mg/ml) was divided by urine creatinine (mg/ml) to
obtain the ratio. Statistical method used was the Pearson’s
correlation coefficient.
59
In our study results were:
? A good correlation existed between the two variables with
r = 0.756 with a highly significant p value = <0.01 when all
the observations were considered.
? When only lesser degrees of proteinuria were taken, the
correlation was good at r = 0.914, p <0.001.
? The correlation at high levels of proteinuria was very poor,
having a negative value and statistically insignificant p
value.
Hence care should be taken while interpreting the
protein/creatinine ratios at severe degrees of proteinuria.
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CONCLUSION
Since the level of urinary protein excretion has considerable
clinical implications in the course of pregnancy, the early detection
of even minor degrees of hyperproteinuria is important.
Dipstick analysis as a screening for proteinuria lacks
reliability with a high rate of false positives.
For years, 24 hour urine collection has been the standard for
quantitation of proteinuria in the management of women with pre-
eclampsia.  However, this method is cumbersome, subjective to
collection errors, requires good patient compliance and results in
the delay in the diagnosis of > 24 hours from the start of collection.
Our contention was that the value of the protein/creatinine ratio in a
single urine sample is potentially more accurate, because it avoids
collection errors and may give more physiologically relevant
information.
Quantitating proteinuria in a random sample has found to be
far more cost effective and acceptable to the patient than a 24 hour
urine collection.
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Since preeclampsia is a progressive disease, repeated
laboratory examinations to quantitate protieinuria are required.
Protein/creatinine ratio has been found to be a superior diagnostic
tool compared to the routine urinalysis which would otherwise be
used for daily quantitation of proteinuria.
Based on the findings of the present study, we conclude that
a random urine protein creatinine ratio predicts the amount of 24
hour urine protein excretion reasonably.  This test could be a
reasonable alternative to the 24 hour urine collection for detection
of significant proteinuria in hospitalised pregnant women with
suspected preeclampsia.
PROFORMA FOR STUDY
NAME :
AGE :
IP. NO. :
ADDRESS :
LMP :
EDD :
GESTATIONAL AGE :
PARITY :
ANY H / SUGGESTIVE OF PREECLAMPSIA  :
H / O PREECLAMPSIA IN PREVIOUS PREGNANCIES  :
FAMILY H / O PREECLAMPSIA  :
H / O HYPERTENSION/REAL DISORDERS / DIABETES / UTI
MEDICATIONS: ANTIHYPERTENSIVES  :
GENERAL EXAMINATION  :
HEIGHT
WEIGHT
ANEMIA
ICTERUS
EDEMA
PULSE
BP
CVS
RS
OBSTETRIC EXAMINATION  :
URINE MICROSCOPY :
URINE PROTEIN BY DIPSTICK TESTING  :
24 HOUR URINARY PROTEIN  :
SPOT PROTEIN CREATININE RATIO  :
BLOOD UREA  :
SERUM CREATININE  :
HEMATOCRIT  :
PLATELET COUNT  :
LIVER FUNCTION TEST  :
FUNDUS EXAMINATION  :
USG:
DOPPLER (WHEREVER INDICATED) :
ABBREVIATIONS
BP -  Blood Pressure
EDD -  Expected Date of Delivery
HELLP -  Hemolysis, Elevated Liver enzmes Low Platelet
IUGR -  Intra Uterine Growth Retardation
LDH -  Lactate dihydrogenase
LMP -  Last Menstrual Period
P value -  Probability value
PCR - Protein to Creatinine Ratio
POG -  Period of Gestation
r -  Pearson’s Correlation Coefficient
SD -  Standard Deviation
SE -  Standard Error
SGOT -  Serum Glutamate Oxaloacetate Transaminase
SGPT -  Serum Glutamate Pyruvate Transaminase
USG - Ultrasonogram
UTI -  Urinary Tract Infection
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S. No. AGE PARITY
SYS
BP
DIA
 BP
GES
AGE
DIPSTICK 24 HUP
SPOT
PCR
REMARKS
1 31 G2P1L1 150 90 36 3+ 4000 8.8
2 23 PRIMI 160 110 27 3+ 5250 2.3
3 27 G2A1 140 90 37 3+ 3250 5.2
4 23 PRIMI 140 96 35 3+ 3366 3.9
5 18 PRIMI 160 100 25 3+ 3270 2.2 Grade II HT Retinopathy
6 25 G3P2L1 140 100 27 4+ 5800 1.72
7 24 PRIMI 150 94 36 3+ 3190 1.7
8 20 PRIMI 150 110 27 4+ 7800 8.2
9 24 PRIMI 150 90 36 3+ 3000 2.5
10 27 PRIMI 150 100 34 3+ 3600 11.39
11 25 PRIMI 140 90 38 3+ 2310 3.5
12 23 PRIMI 140 94 36 3+ 1120 1.83
13 22 PRIMI 150 90 36 4+ 1546 3.4
14 20 G2P1L1 160 100 33 3+ 1454 3.11 Recurrent Preeclampsia
15 31 PRIMI 140 90 36 3+ 1220 0.98
16 23 PRIMI 150 100 33 4+ 1840 3.32
S. No. AGE PARITY
SYS
BP
DIA
 BP
GES
AGE
DIPSTICK 24 HUP
SPOT
PCR
REMARKS
17 22 G2P1L0 150 110 34 3+ 1176 1.02 IUGR, Rec.  Preeclampsia
18 26 PRIMI 140 90 36 3+ 1020 2.12
19 20 PRIMI 160 100 32 2+ 2546 2.2
20 31 G2A1 160 90 39 1+ 963 1.2
21 30 PRIMI 160 100 33 1+ 631 0.76
22 32 G2P1L1 150 110 38 3+ 984 1.02
23 28 PRIMI 140 110 34 1+ 756 0.92
24 31 PRIMI 170 100 33 1+ 640 0.58 Grade II HT Retinopathy
25 29 PRIMI 160 104 35 1+ 386 0.4
26 29 G2P1L1 160 90 38 1+ 482 0.52
27 20 G2P1L1 150 110 34 1+ 570 0.48
28 27 G3P1L1A1 160 96 36 2+ 960 1.4
29 19 PRIMI 140 110 32 1+ 824 1.2
30 19 PRIMI 160 90 37 1+ 1140 2.12
31 21 PRIMI 160 100 34 1+ 874 1.12
32 32 PRIMI 160 100 34 2+ 1134 0.98
33 23 G2P1L1 140 90 39 1+ 420 0.81 IUGR
S. No. AGE PARITY
SYS
BP
DIA
 BP
GES
AGE
DIPSTICK 24 HUP
SPOT
PCR
REMARKS
34 18 PRIMI 150 110 34 2+ 824 0.77
35 24 G2P1L1 140 110 33 2+ 740 0.76
36 25 G2A1 170 90 36 1+ 524 0.66
37 18 PRIMI 170 90 36 1+ 840 0.92
38 19 PRIMI 160 110 26 2+ 920 1.1
39 18 PRIMI 160 100 38 2+ 560 0.68 PP Eclampsia
40 21 PRIMI 160 100 35 1+ 840 1.32
41 19 PRIMI 150 110 33 2+ 767 1.01
42 23 PRIMI 150 100 34 2+ 1320 2.56 IUGR
43 20 G2P1L1 160 90 36 1+ 760 0.92
44 22 PRIMI 150 110 35 2+ 640 0.81
45 35 PRIMI 160 100 35 1+ 520 0.61
46 23 PRIMI 140 110 37 2+ 970 2.1
47 22 PRIMI 140 110 34 2+ 848 0.96
48 31 G3P2L0 140 100 36 2+ 340 0.18 IUGR, Rec.  Preeclampsia
49 26 G2P1L1 160 110 32 2+ 980 1.45
50 31 PRIMI 130 94 36 2+ 1324 2.2 IUGR
S. No. AGE PARITY
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BP
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 BP
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DIPSTICK 24 HUP
SPOT
PCR
REMARKS
51 18 PRIMI 150 80 30 1+ 356 0.41
52 25 G3P1L1A1 150 94 38 2+ 1370 2.1 PP Eclampsia
53 20 PRIMI 140 90 39 2+ 878 0.76 IUGR
54 34 G3P2L1 150 80 27 1+ 422 0.63
55 33 G3P2L1 150 90 39 2+ 1140 1.45 IUGR
56 31 G2P1L1 140 90 37 1+ 550 0.48
57 31 G2P1L1 130 100 38 1+ 448 0.48
58 31 PRIMI 150 90 39 1+ 720 0.8
59 33 G2P1L1 140 90 27 1+ 325 0.32
60 19 PRIMI 140 90 39 1+ 960 1.2 PP Eclampsia
61 32 G2P1L1 150 90 40 1+ 548 0.82
62 32 G2P1L0 150 100 37 1+ 842 1.32 Recurrent Preeclampsia
63 19 PRIMI 130 100 38 2+ 1323 2.1
64 18 PRIMI 140 90 34 1+ 776 0.74
65 20 G2P1L1 150 90 34 1+ 645 0.89
66 19 PRIMI 150 90 33 1+ 440 0.74
67 27 PRIMI 140 90 35 1+ 732 0.59 IUGR
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PCR
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68 20 G2P1L1 150 90 34 1+ 648 0.48
69 19 PRIMI 150 80 30 1+ 572 0.67
70 18 PRIMI 130 100 36 2+ 1154 1.72
71 20 G2P1L1 150 90 35 1+ 476 0.52
72 19 PRIMI 150 100 36 2+ 996 1.32
73 19 PRIMI 140 100 36 1+ 760 0.82
74 18 PRIMI 150 84 34 1+ 376 0.51
75 19 G3P1L1A1 140 100 36 2+ 292 0.37
76 20 PRIMI 140 96 37 1+ 960 1.8
77 20 PRIMI 130 96 38 1+ 320 0.36
78 19 PRIMI 140 86 34 1+ 700 0.88
79 18 PRIMI 150 90 38 1+ 640 0.46
80 20 PRIMI 140 86 37 1+ 348 0.28
81 20 PRIMI 140 100 36 2+ 870 1.23
82 19 PRIMI 150 94 40 1+ 135 0.16
83 22 G2P1L1 130 100 25 1+ 138 0.19
84 27 PRIMI 140 90 38 1+ 742 0.96
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PCR
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85 26 PRIMI 130 90 26 1+ 198 0.2
86 24 G2P1L1 140 86 39 1+ 380 0.43
87 24 G2P1L1 140 100 36 1+ 476 0.53
88 23 PRIMI 150 90 36 1+ 560 0.61
89 28 G3P2L2 150 80 33 1+ 154 0.19
90 21 PRIMI 150 94 38 1+ 254 0.29
91 30 G3P2L1 140 90 32 1+ 200 0.21
92 22 G2P1L1 130 96 34 1+ 285 0.37
93 25 PRIMI 150 90 35 1+ 220 0.25
94 25 PRIMI 154 90 35 1+ 576 0.67
95 26 G3P1L1A1 140 86 36 1+ 220 0.24
96 26 PRIMI 140 90 35 1+ 530 0.76
97 26 G2P1L1 150 94 37 2+ 3550 1.9 Recurrent Preeclampsia
98 24 PRIMI 150 100 36 2+ 1220 1.52
99 23 PRIMI 130 100 37 1+ 970 0.84
100 22 PRIMI 140 94 37 1+ 135 0.16
101 21 PRIMI 140 86 38 1+ 221 0.93
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102 28 G2P1L1 140 100 37 2+ 1030 1.8
103 23 PRIMI 130 94 37 2+ 1190 1.6
104 29 G2P1L1 130 90 29 1+ 236 0.22
105 24 PRIMI 140 90 37 1+ 530 0.28
106 21 G2P1L1 150 100 36 2+ 766 0.92
107 29 PRIMI 154 90 37 1+ 480 1.04
108 24 G2P1L1 144 80 38 1+ 320 0.41
109 24 PRIMI 140 90 38 2+ 851 1.2
110 26 PRIMI 130 90 28 1+ 420 0.39
111 27 PRIMI 140 80 29 2+ 544 0.76
112 25 PRIMI 150 84 37 1+ 480 0.46
113 24 G2P1L1 130 100 37 1+ 424 0.57
114 23 PRIMI 140 90 38 2+ 880 1.19
115 21 G2P1L1 150 84 35 1+ 490 0.76
116 25 PRIMI 150 90 36 1+ 490 0.52
117 29 G3P1L1A1 136 90 38 1+ 670 0.88
118 26 G2P1L1 140 94 37 1+ 250 0.27
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119 28 G2P1L1 140 100 35 2+ 842 1.1
120 24 G3A2 140 90 36 1+ 860 1.3
121 30 G3P2L1 130 96 37 2+ 821 1.1
122 23 PRIMI 140 90 37 1+ 525 0.6
123 27 PRIMI 130 90 27 1+ 235 0.31
124 22 G2P1L1 130 94 39 1+ 240 0.2
125 21 PRIMI 150 90 37 1+ 376 0.42
126 27 G2P1L0 140 100 35 1+ 476 0.61
127 30 G3P1L0A1 150 100 36 2+ 1450 2.42 Recurrent Preeclampsia
128 37 G3P2L2 140 80 26 1+ 180 0.17
129 26 PRIMI 150 80 27 1+ 176 0.18
130 26 G3P2L2 140 90 34 1+ 676 0.89
131 23 G2P1L1 150 90 35 1+ 490 0.57
132 21 G2P1L1 130 94 35 2+ 978 1.2
133 0 PRIMI 130 90 27 1+ 145 0.13
134 22 PRIMI 140 94 36 2+ 1170 1.52
135 23 G2P1L1 130 94 39 1+ 842 1.43
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BP
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PCR
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136 25 PRIMI 150 86 34 1+ 456 0.67
137 28 G2P1L1 140 90 34 1+ 620 0.77
138 27 G2P1L1 130 90 36 1+ 188 0.19
139 26 PRIMI 150 90 39 1+ 450 0.39
140 26 G2P1L1 140 90 24 1+ 235 0.22
141 25 PRIMI 130 90 40 1+ 176 0.19
142 24 G2A1 140 86 33 1+ 200 0.19
143 24 PRIMI 150 86 34 1+ 242 0.3
144 22 PRIMI 150 94 25 1+ 240 0.27
145 21 G2P1L1 140 90 34 1+ 268 0.31
146 30 G3P1L1A1 130 90 34 1+ 272 0.25
147 21 PRIMI 130 90 24 1+ 132 0.15
148 28 G2P1L1 150 84 33 1+ 276 0.31
149 26 G2P1L1 144 84 33 1+ 290 0.42
150 25 G2P1L1 140 90 35 1+ 186 0.16
